MEDICAMEN BIOTECH
|
The Current P/E Ratio of MEDICAMEN BIOTECH is 52.22.
| Share Price | ₹277.1 | May 13,2026 |
| Market Cap | ₹376.8 Cr | |
| Earnings-TTM | ₹7.2 Cr | TTM-Consolidated Results |
| Price/Earnings | 52.22x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of MEDICAMEN BIOTECH
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹376.8 Cr] as on May 13,2026
(/) Earnings [ ₹7.2 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 52.22x ]
Thus, for MEDICAMEN BIOTECH , the investors are currently willing to pay 52.22 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of MEDICAMEN BIOTECH !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of MEDICAMEN BIOTECH over the last five years.
Historical PE (Price/Earnings) ratio chart of MEDICAMEN BIOTECH
PE Ratio Performance Analysis for MEDICAMEN BIOTECH
- MEDICAMEN BIOTECH 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 61.52x.
- MEDICAMEN BIOTECH 's operated at median p/e ratio of 53.78x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, MEDICAMEN BIOTECH 's p/e ratio peaked in Mar2025 at 93.43x.
- MEDICAMEN BIOTECH 's p/e ratio hit its five-year low in Mar2024 of 51.31x.
How does MEDICAMEN BIOTECH 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| MEDICAMEN BIOTECH | 7.22 | 52.22 | 376.8 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,001.40 | 39.79 | 437,735.0 |
| DIVIS LABORATORIES LTD | 2,479.00 | 72.74 | 180,312.0 |
| CIPLA LTD | 3,869.79 | 27.70 | 107,205.0 |
| TORRENT PHARMACEUTICALS LTD | 2,272.00 | 63.98 | 145,369.0 |
| DR REDDYS LABORATORIES LTD | 4,144.20 | 25.48 | 105,592.0 |
| MANKIND PHARMA LTD | 1,796.65 | 55.32 | 99,384.3 |
| ZYDUS LIFESCIENCES LTD | 4,933.90 | 19.15 | 94,480.3 |
| LUPIN LTD | 5,355.47 | 18.91 | 101,294.0 |
| AUROBINDO PHARMA LTD | 3,513.20 | 24.76 | 86,978.0 |
| ABBOTT INDIA LTD | 1,552.02 | 37.32 | 57,928.2 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs MEDICAMEN BIOTECH 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 18.91x |
| Max industry PE | 72.74x |
| Median industry PE | 37.32x |
| Average industry PE | 39.76x |
You may also like the below Video Courses